255 related articles for article (PubMed ID: 33028228)
1. Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach.
Li W; Chang TS; Chang SZ; Chen CH; Chen MY
BMC Infect Dis; 2020 Oct; 20(1):737. PubMed ID: 33028228
[TBL] [Abstract][Full Text] [Related]
2. Liver Health Literacy and Health Status Among Adults With Hepatitis C: Implications for the Nursing Profession as Part of the 2030 Global Elimination Goal.
Lin YC; Chiu WN; Chang TS; Huang TJ; Chen MY
J Nurs Scholarsh; 2020 Mar; 52(2):128-135. PubMed ID: 31750620
[TBL] [Abstract][Full Text] [Related]
3. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
4. Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care.
Tien HM; Cheng TC; Lien HC; Yang KF; Shy CG; Chen YL; Hsu NT; Lu SN; Wang JH
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35328957
[TBL] [Abstract][Full Text] [Related]
5. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
[TBL] [Abstract][Full Text] [Related]
6. Collaborative Referral Model for Hepatitis C Screening and Treatment in a Remote Mountainous Region of Taiwan during the COVID-19 Pandemic.
Tai CM; Bair MJ; Chen TH; Tseng CH; Chen CC; Lam H; Yu ML
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112808
[TBL] [Abstract][Full Text] [Related]
7. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
8. Change in hepatitis C virus positivity among needle-stick injury source patients: a 10-year experience in a Japanese tertiary hospital.
Okushin K; Suzuki R; Tsutsumi T; Okamoto K; Ikeuchi K; Kado A; Minatsuki C; Minami-Kobayashi Y; Satoh N; Ikeda M; Harada S; Enooku K; Fujinaga H; Yotsuyanagi H; Koike K; Moriya K
BMC Infect Dis; 2021 Apr; 21(1):399. PubMed ID: 33931015
[TBL] [Abstract][Full Text] [Related]
9. An Investigation of the Side Effects, Patient Feedback, and Physiological Changes Associated with Direct-Acting Antiviral Therapy for Hepatitis C.
Wu PS; Chang TS; Lu SN; Su HJ; Chang SZ; Hsu CW; Chen MY
Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31817863
[No Abstract] [Full Text] [Related]
10. Hospital-Based Hepatitis C Screening of Baby Boomers in a Majority Hispanic South Texas Cohort: Successes and Barriers to Implementation.
Taylor BS; Hanson JT; Veerapaneni P; Villarreal R; Fiebelkorn K; Turner BJ
Public Health Rep; 2016; 131 Suppl 2(Suppl 2):74-83. PubMed ID: 27168665
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
Sagnelli E; Stroffolini T; Sagnelli C; Cacopardo B; Andriulli A; Babudieri S; Coppola N; Gaeta GB; Almasio PL
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):676-681. PubMed ID: 29465473
[TBL] [Abstract][Full Text] [Related]
12. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
13. Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach.
Kamali I; Barnhart DA; Nyirahabihirwe F; de la Paix Gakuru J; Uwase M; Nizeyumuremyi E; Walker S; Mazimpaka C; de Dieu Gatete J; Makuza JD; Serumondo J; Kateera F; d'Amour Ndahimana J
BMC Infect Dis; 2021 Feb; 21(1):220. PubMed ID: 33632165
[TBL] [Abstract][Full Text] [Related]
14. Measuring Adherence to Hepatitis C Direct-Acting Antiviral Medications: Using the VAS in an HCV Treatment Clinic.
Burton MJ; Voluse AC; Patel AB; Konkle-Parker D
South Med J; 2018 Jan; 111(1):45-50. PubMed ID: 29298369
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations.
Turner BJ; Rochat A; Lill S; Bobadilla R; Hernandez L; Choi A; Guerrero JA
Ann Intern Med; 2019 Dec; 171(12):865-874. PubMed ID: 31791065
[TBL] [Abstract][Full Text] [Related]
16. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
[TBL] [Abstract][Full Text] [Related]
17. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
18. Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients.
Komatsu F; Takasaki K
Liver; 1999 Oct; 19(5):375-80. PubMed ID: 10533794
[TBL] [Abstract][Full Text] [Related]
19. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.
van Tilborg M; Al Marzooqi SH; Wong WWL; Maan R; Vermehren J; Maasoumy B; Mazzulli T; Bolotin S; Garber G; Guerra F; Flud CR; Kowgier M; Janssen HL; de Knegt RJ; Pawlotsky JM; Cloherty GA; Duarte-Rojo A; Sarrazin C; Wedemeyer H; Feld JJ
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):856-864. PubMed ID: 30274834
[TBL] [Abstract][Full Text] [Related]
20. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.
Seo KI; Yun BC; Li WJ; Lee SU; Han BH; Park ET
Clin Mol Hepatol; 2017 Mar; 23(1):74-79. PubMed ID: 28259115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
